Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Bloodworks maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. Currently, there are 2 pending office actions in the portfolio. These actions are assigned to 2 distinct examiners and are located in 2 distinct art units, showing a distributed approach to its current biotechnology filings.
The busiest examiner for the portfolio is KIM, TAEYOON, who is responsible for 1 pending office action. With 2 pending office actions total and 2 distinct examiners, the current workload is divided equally. The involvement of 2 distinct art units indicates that the company's biotechnology applications are being processed across different specialized groups within the patent office. This distribution requires the company to navigate the specific examination cultures of 2 different art units and 2 different examiners simultaneously for its 2 pending matters. For a practitioner, managing 2 distinct examiners in 2 different art units for only 2 pending actions indicates a highly fragmented prosecution landscape for the company's biotechnology assets.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, TAEYOON | 1 | 51.4% | +52.2% |
| NGUYEN, NAM P | 1 | 54.8% | +48.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18444289 | TARGETING VON WILLEBRAND FACTOR TO MODEL DISEASE IN HUMAN PLURIPOTENT STEM CELLS | KIM, TAEYOON | — |
| 16966809 | ANTIBODY SCREENS USING TRANSGENIC ANTIGEN(S) | NGUYEN, NAM P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18444289 | TARGETING VON WILLEBRAND FACTOR TO MODEL DISEASE IN HUMAN PLURIPOTENT STEM CELLS | KIM, TAEYOON | — |
| 16966809 | ANTIBODY SCREENS USING TRANSGENIC ANTIGEN(S) | NGUYEN, NAM P | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18444289 | TARGETING VON WILLEBRAND FACTOR TO MODEL DISEASE IN HUMAN PLURIPOTENT STEM CELLS | KIM, TAEYOON | 1631 | §101§103§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 16966809 | ANTIBODY SCREENS USING TRANSGENIC ANTIGEN(S) | NGUYEN, NAM P | 1678 | §103§112Other | Final Rejection | — | Pending | Jul 31, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBloodworks has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Taeyoon Kim has the most, with 1 of Bloodworks's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
